Aventis/TKT Dynepo Regulatory Review Commences, Patent Suit Continues
Executive Summary
The regulatory pathway of gene-activated erythropoietin Dynepo is evidence that the product is not equivalent to Amgen's Epogen, Aventis Chief Scientific Officer Frank Douglas, MD/PhD, said July 18 in Boston federal court.